Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
In this article:
Advertisement
Recommended Stories
Forget Nvidia: Members of Congress Are Scooping Up Shares of Its Core Rival Instead
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Motley Fool•Trump to set interest rates himself under secret presidential plan
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
The Telegraph•Nvidia Owns a 3.4% Stake in This Innovative Artificial Intelligence (AI) Stock Cathie Wood Loves
The $50 million purchase could turn into Nvidia's biggest investment.
Motley Fool•2 Stock-Split Stocks to Buy Hand Over Fist Right Now
These proven wealth builders could be exactly what you're searching for right now.
Motley Fool•Housing supply surges by up to 50% in these metro areas — and many sellers are being forced to slash their asking prices
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
MarketWatch•Walmart CEO started his career unloading trailers at the warehouse—he says he got promotion after promotion by raising his hand when his boss was out of town
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
Fortune•Why I Just Added This Ultra-High-Yield Dividend ETF to My Retirement Account
The JPMorgan Nasdaq Equity Premium Income ETF offers a compelling blend of income and upside to my portfolio.
Motley Fool•U.S. panic over national debt might mark a culture shift—are Americans becoming more ‘European’ about money?
Jamie Dimon and Jerome Powell are taking the European viewpoint on soaring debt levels in the U.S.
Fortune•Worried About a Stock Market Sell-Off? Buy This Top Vanguard ETF
There are benefits to investing in stocks that have reasonable multiples and aren't as dependent on future earnings growth to justify their valuations.
Motley Fool•Analysts revamp Microsoft stock price target after earnings
Here's what could happen next to Microsoft shares.
TheStreet•